NervGen Pharma Corp. announced that it has appointed Denis Bosc, PhD, as the company's Vice President, Chemistry, Manufacturing and Control (CMC). In addition, Paul Brennan has joined the NervGen team to advise on strategy and business development. Dr. Bosc has a demonstrated history of working with a variety of drug substance and drug product CDMOs for programs at different stages of pharmaceutical development, including preclinical to commercial products. He joins NervGen from the Centre for Probe Development and Commercialization ("CPDC"), a Canadian center of excellence for commercialization and research, where he was Director, Radiopharmaceutical Development and Supply. Prior to CPDC, Dr. Bosc was VP, R&D at Impopharma, a company specializing in the development of nasal spray and pulmonary inhalation drug products. Dr. Bosc's CMC experience also includes positions at Apotex Inc. and SteriMax, both commercial stage companies, YM BioSciences, a small molecule pharmaceutical company acquired by Gilead Sciences for $580 million, and Viventia Biotech, an antibody therapeutic development company. Mr. Brennan began his pharmaceutical business development career as the Director of Global Licensing at Astra (now part of AstraZeneca), where he was responsible for product licensing, technology evaluation and acquisitions in the respiratory and inflammatory diseases area. Subsequently, he served as the VP of Business Development at AnorMED which was acquired by Genzyme in 2006 for $580 million, and for Aspreva which was acquired by Galenica in 2007 for $915 million. Notably, Mr. Brennan has also served as VP of Business Development at Aquinox Pharmaceuticals, and as Senior VP of Business Development at Tekmira Pharmaceuticals. Mr. Brennan has a comprehensive list of business development and licensing transactions for which he played a lead role, including mergers & acquisitions, in-licensing, out-licensing, regional transactions, corporate restructuring and dispute resolutions.